Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss key factors guiding frontline therapy selection in EGFR-mutated NSCLC.
Back
Refining Therapeutic Approaches in EGFR-Mutated Non–Small Cell Lung Cancer
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss frontline treatment considerations in EGFR-mutated advanced non–small cell lung cancer.
Refining Therapeutic Approaches in EGFR-Mutated Non–Small Cell Lung Cancer
Episodes
All
All
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss treatment strategies for EGFR-mutated NSCLC with high-risk clinical features.
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss the clinical role of amivantamab plus lazertinib in EGFR-mutated NSCLC.
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss adverse event management with subcutaneous amivantamab.
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss how frontline therapy selection influences sequencing in EGFR-mutated NSCLC.
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss toxicity considerations with ADCs and emerging therapies in EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
4
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
5